Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.69 |
| ▸ | BACE1 | P56817 | 13/20 | 0.69 |
| ▸ | BCHE | P06276 | 12/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL724604 | 1.00 | ACHE (0.69) | ACHEBACE1BCHEDRD2DRD4 | |
| SCHEMBL242759 | 1.00 | ACHE (0.69) | ACHEBACE1BCHEDRD2DRD4 | |
| Bromide SCHEMBL2497824 | 0.98 | ACHE (0.68) | ACHEBACE1BCHEDRD2DRD4 | |
| SCHEMBL2734633 | 0.91 | DRD2 (0.61) | ACHEBACE1BCHEDRD2DRD4 | |
| SCHEMBL2730825 | 0.90 | CYP1A2 (0.60) | ACHEBACE1BCHE | |
| SCHEMBL350928 | 0.90 | CYP1A2 (0.60) | ACHEBACE1BCHE | |
| SCHEMBL6128786 | 0.90 | CYP1A2 (0.60) | ACHEBACE1BCHE | |
| SCHEMBL360075 | 0.90 | ACHE (0.68) | ACHEBACE1BCHEDRD2DRD4 | |
| Hydrochloric Acid SCHEMBL5862090 | 0.88 | ACHE (0.66) | ACHEBACE1BCHEDRD2DRD4 | |
| Hydrochloric Acid SCHEMBL8055676 | 0.88 | ACHE (0.66) | ACHEBACE1BCHEDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| CN-111718250-B | Method for preparing R-citronellal | 万华化学集团股份有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-111718250-A | Method for preparing R-citronellal | 万华化学集团股份有限公司 | 2020-09-29 | — | — | CN | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| US-20060270847-A1 | Process for producing nitrogenous heterocyclic compound | TORAY FINE CHEMICALS CO., LTD. (JP) | 2006-11-30 | — | — | US | claimed |
| EP-1640364-A1 | PROCESS FOR PRODUCING NITROGENOUS HETEROCYCLIC COMPOUND | Toray Fine Chemicals Co., Ltd. (JP) | 2006-03-29 | — | — | EP | claimed |
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | claimed |
| US-20040259887-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-12-23 | — | — | US | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | claimed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| US-4874760-A | CALCIUM ANTAGONISTS | TOA EIYO, LTD. (JP) | 1989-10-17 | — | — | US | disclosed |
| EP-0277701-A1 | Thiazolopyridine derivative, their production and cardiovascular treating agents containing them | TOA EIYO LTD. (JP) | 1988-08-10 | — | — | EP | disclosed |
| EP-0132845-B1 | NOVEL 1,8-NAPHTHYRIDINE DERIVATIVES, AND PROCESS FOR PREPARATION THEREOF | Dainippon Pharmaceutical Co., Ltd. (JP) | 1988-04-13 | — | — | EP | disclosed |
| US-4649144-A | Antibacterial 7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid derivatives | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1987-03-10 | — | — | US | disclosed |
| EP-0132845-A2 | Novel 1,8-Naphthyridine derivatives, and process for preparation thereof | Dainippon Pharmaceutical Co., Ltd. (JP) | 1985-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259887-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | ACHE 1631/4885BACE1 1133/4885BCHE 1548/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | ACHE 3656/4885BACE1 1001/4885BCHE 3812/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | ACHE 3173/4885BACE1 2709/4885BCHE 938/4885 |
| US-20060270847-A1 | Process for producing nitrogenous heterocyclic compound | HNMT, HRH4, QDPR | ACHE 671/4885BACE1 1432/4885BCHE 782/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | ACHE 206/4885BACE1 18/4885BCHE 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.